KCT0002079已完成未知
igh post-remission WT1 expression is a predictive marker for subsequent molecular relapse and poor survival in adult patients with acute promyelocytic leukemia (APL)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 117
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) 18 years and older
- •2) Acute promyelocytic leukemia confirmed by t(15;17) karyotype or molecular marker such as PML-RARa
- •3) Acute promyelocytic leukemia in first hematological remission after induction chemotherapy followed by at least 2 consolidation chemotherapy
- •4) Patients with available WT1 expression results until 6 months after finishing last consolidation therapy
排除标准
- •1) Under 18 years old
- •2) Hematological malignancies without an evidence of t(15;17) karyotype or molecular marker such as PML-RARa
- •3) Acute promyelocytic leukemia in treatment failure after induction chemotherapy
- •4) Patients without available WT1 expression results
研究者
相似试验
已完成
Unknown
Measurement of WT1-mRNA in Acute Myeloid Leukemia PatientsAcute Myeloid LeukemiaJPRN-jRCT1090220061Shuichi Miyawaki;Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital.100
已完成
Unknown
Prognostic Potential of Detection of WT1-mRNA in Acute Myeloid LeukemiaAcute myeloid leukemia (AML)JPRN-jRCT1090220039Shuichi Miyawaki;Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital.50
招募中
不适用
Significance of WT1 mRNA in the clinical course of lower-risk myelodysplastic syndromes.lower-risk myelodysplastic syndromesJPRN-UMIN000017862Jichi Medical University100
进行中（未招募）
不适用
Efficacy of WT1-peptide vaccination for remission maintenance in patients with acute myeloid leukemia: A controlled phase II trial - WT1-peptide studyacute myeloid leukemiaPatients with acute myeloid leukemia in 1st or 2nd CR or leukemia-free state are eligible for this study. Patients in 1st CR must have unfavorable prognostic factors. Definition of high-risk patients in 1st CR include: Unfavourable cytogenetics (abnormalities of 3, 5, 7 or complex karyotype)normal karyotype and no CR after 1st induction therapy or no or incomplete consolidation chemotherapy.MedDRA version: 8.1Level: LLTClassification code 10000887Term: Acute myeloid leukemia in remissionEUCTR2005-005242-39-DECharité Campus Benjamin Franklin, Med. Clinic III,Dept. of Hematology,Oncology, Transfusion Medicine122
已完成
不适用
Effect of the safety and recurrence of WT1- specific cytotoxic T lymphocytes (CTL) therapy in the treatment of high-risk acute myeloid leukemia, myelodysplastic syndromeKCT0002515The Catholic University of Korea, Seoul St. Mary's Hospital10